<DOC>
	<DOC>NCT02386072</DOC>
	<brief_summary>A study to identify factors that are associated with improved effectiveness in pharmacologic therapy of Overactive Bladder, from the patient perspective primarily measured by OAB-Q-SF (Overactive Bladder Questionnaire Short Form)</brief_summary>
	<brief_title>A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Urinary Bladder Diseases</mesh_term>
	<mesh_term>Urologic Diseases</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<mesh_term>Muscarinic Antagonists</mesh_term>
	<criteria>Diagnosed with OAB (with or without urgency incontinence) by the treating HCP, with symptoms for at least three months prior to study enrollment Initiating a new course of treatment with mirabegron or antimuscarinic medication (including patch formulation) for OAB, which may be first course of any treatment for OAB, restart or switch from one drug to another Willing and able to complete PRO questionnaires with minimal assistance Current participation in clinical trials of OAB Use of more than one OAB medication at time of enrollment Patients whose OAB has been treated with onabotulinumtoxinA, sacral neuromodulation, percutaneous tibial nerve stimulation, external beam radiation (XRT), stents, surgery, or intermittent catheterization prior to or at time of enrollment Neurologic conditions associated with OAB symptoms Patients residing in a nursing home</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Betanis®</keyword>
	<keyword>Myrbetriq®</keyword>
	<keyword>Quality of Life</keyword>
	<keyword>Antimuscarinics</keyword>
	<keyword>Betmiga®</keyword>
	<keyword>Overactive Bladder</keyword>
	<keyword>Observational</keyword>
</DOC>